about
Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study.Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertensionNovel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study.Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients.Nordic Longitudinal Data from Electronic Medical Records and Full Population National Registers: Unique Opportunities for New Insights in Benefit of Diabetes Patients.Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013.Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting.Possible angina detected by the WHO angina questionnaire in apparently healthy men with a normal exercise ECG: coronary heart disease or not? A 26 year follow up study.Interaction between inflammation and blood viscosity predicts cardiovascular mortality.Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients.Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary heart disease mortality risk.Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan.Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study.Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure.Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns.Low heart rates predict incident atrial fibrillation in healthy middle-aged men.Exercise testing of healthy men in a new perspective: from diagnosis to prognosis.Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients.Symptom-limited exercise testing, ST depressions and long-term coronary heart disease mortality in apparently healthy middle-aged men.Seven-year increase in exercise systolic blood pressure at moderate workload predicts long-term risk of coronary heart disease and mortality in healthy middle-aged men.Reasons for terminating an exercise test provide independent prognostic information: 2014 apparently healthy men followed for 26 years.Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men.Association of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden.Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study.Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice.Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational studyComment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10[Long term prognosis in relation to the presence of systolic heart murmurs in healthy middle-aged men][Exercise ECG]Early Versus Late Morning Measurement of Blood Pressure in Healthy Men. A Potential Source of Measurement Bias?How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational studyDapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational studyDapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational studyHeart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study
P50
Q33450125-4DEE32B2-E3A9-43BE-871C-943F395FA848Q33710477-EFA043FD-0754-4F62-A2DF-4344E8267CEDQ33835709-6B375BB6-2DBE-437E-845C-F2AD68A9DE2CQ34985247-D0CE6C17-D501-49D4-B3AA-36A2FB6515F8Q35044192-E13B013F-BA04-42F2-BBFC-12BA000127A9Q35831514-5441561D-0B97-42CC-9565-BEB832AA9910Q39759073-E883085C-7AF9-4ED7-BC5A-18388CE1A72CQ40394680-C147F3B3-2FA3-4AA3-AF73-55109EE8719BQ40689127-7B352CB6-1EFB-4927-8107-EC52A0F60BA9Q41511886-EE2E2083-806B-4A93-A24D-968C278E0CB6Q42061177-00A25137-6B81-4F30-A9AF-2D48B3541760Q43294345-FED94B5C-18D7-41C2-969E-111BDCAACF4AQ43448428-0396ABDA-9E7D-4D71-A1AB-63F47429D282Q43568764-64F408A9-B99C-40BF-9CD0-C640F26C3BEDQ43863358-6DE2ECBC-A8BA-44F4-B77F-65A83DEFDAECQ44330951-1A805703-63B6-4E3E-9B8D-30D715438D92Q44484670-621DD64D-01E8-4E5F-A1CE-B7939A89116DQ44665525-07EBDD27-3C40-4B91-96A6-01EA0317CBCCQ44763977-63199EAD-6F2E-4445-9B41-88C2AF1FCA14Q44917527-CF3DB039-7789-4CB2-9AD0-60F5D6FE7C50Q45004504-F78BE613-2A3E-4BEE-9B32-B3ECC68E04FFQ45006363-F20A8BA5-7D14-473E-8ED7-B524899DB651Q45129716-B468C92A-E927-4238-8326-E8601F6B0789Q46458520-E0751010-6EA2-40E8-99AF-BF4782D5B3AEQ47310606-798E2D21-89C3-4714-8F24-2FA1CD195F67Q47427972-A3FCE48E-EDFC-4A03-9014-3F4553BD39FDQ48248419-41BB2C42-B0C8-4906-A5C3-AC5EC8AA6E2BQ48296619-7AA27B5F-7A74-42B8-999F-1691AE867616Q51039594-C802157C-1B7C-41C2-B981-E49AAE149728Q57829729-1193E4AD-F576-4459-9158-7A3EEFB579EFQ57829734-9AFFD27A-64C6-4C02-82B9-F25099486D87Q57829842-EDBDEECC-6B42-42B8-ABD5-D85D3638EB48Q57829856-444E5394-26C1-4714-A921-D907C939D5E3Q57829866-B0DFE1E7-941E-4005-99A2-2326742EBC66Q90405435-BA2ADDAE-025E-420A-BA83-0A07F3AFCA2DQ90883165-D9C19726-7801-4067-A4D8-42DACDD7C9C6Q92399903-6A10AC12-CCD2-4CAC-94CB-384DB72E8414Q94505009-0A69C31F-1A55-4886-B268-20343782144C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Johan Bodegard
@ast
Johan Bodegard
@en
Johan Bodegard
@es
Johan Bodegard
@nl
Johan Bodegard
@sl
type
label
Johan Bodegard
@ast
Johan Bodegard
@en
Johan Bodegard
@es
Johan Bodegard
@nl
Johan Bodegard
@sl
prefLabel
Johan Bodegard
@ast
Johan Bodegard
@en
Johan Bodegard
@es
Johan Bodegard
@nl
Johan Bodegard
@sl
P1053
B-8398-2017
P106
P21
P31
P3829
P496
0000-0001-5423-3967